Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

85.86 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

22 23 Next >

Exploring the Growth Potential of NASDAQ:CORT as It Nears a Breakout. ↗

January 15, 2025

CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a strong growth stock, setting up for a breakout.

Via Chartmill

NASDAQ:CORT is not too expensive for the growth it is showing. ↗

January 10, 2025

For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering.

Via Chartmill

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism

December 30, 2024

From Corcept Therapeutics Incorporated

Via Business Wire

Exploring high growth characteristics of CORCEPT THERAPEUTICS INC (NASDAQ:CORT). ↗

December 12, 2024

Exploring high growth characteristics of CORCEPT THERAPEUTICS INC (NASDAQ:CORT).

Via Chartmill

NASDAQ:CORT, a strong growth stock, setting up for a breakout. ↗

December 12, 2024

CORCEPT THERAPEUTICS INC (NASDAQ:CORT) qualifies as a high growth stock and is consolidating.

Via Chartmill

In the world of growth stocks, NASDAQ:CORT shines as a value proposition. ↗

November 04, 2024

Looking for growth without the hefty price tag? Consider NASDAQ:CORT.

Via Chartmill

Investors should take note of NASDAQ:CORT, a growth stock that remains attractively priced. ↗

December 20, 2024

CORCEPT THERAPEUTICS INC (NASDAQ:CORT) stands out as a growth opportunity that won't break the bank.

Via Chartmill

Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism

December 16, 2024

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes ↗

December 13, 2024

Corcept Therapeutics reports positive Phase 4 CATALYST results, showing Korlym significantly improves hemoglobin A1c in hypercortisolism patients.

Via Benzinga

Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes

December 12, 2024

From Corcept Therapeutics Incorporated

Via Business Wire

Earnings Preview: Corcept Therapeutics ↗

October 29, 2024

Via Benzinga

Key Takeaways From Corcept Therapeutics Analyst Ratings ↗

October 18, 2024

Via Benzinga

Is NASDAQ:CORT suited for high growth investing? ↗

October 17, 2024

Should you consider CORCEPT THERAPEUTICS INC (NASDAQ:CORT) for high growth investing?

Via Chartmill

Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)

December 11, 2024

From Corcept Therapeutics Incorporated

Via Business Wire

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating ↗

December 11, 2024

NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.

Via Investor's Business Daily

For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering. ↗

November 28, 2024

NASDAQ:CORT is showing decent growth, but is still valued reasonably.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 30, 2024

Via Benzinga

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update

October 30, 2024

From Corcept Therapeutics Incorporated

Via Business Wire

NASDAQ:CORT: a strong growth stock preparing for the next leg up?. ↗

October 14, 2024

Is CORCEPT THERAPEUTICS INC (NASDAQ:CORT) on the Verge of a Major Breakout as a Strong Growth Stock?

Via Chartmill

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

October 23, 2024

From Corcept Therapeutics Incorporated

Via Business Wire

Investors seeking growth at a reasonable cost should explore NASDAQ:CORT. ↗

October 08, 2024

NASDAQ:CORT is not too expensive for the growth it is showing.

Via Chartmill

Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast ↗

September 30, 2024

Truist Securities raises the price target for Corcept Therapeutics to $76, driven by robust Korlym sales and promising relacorilant trials. The analyst highlights significant growth potential in the...

Via Benzinga

Forecasting The Future: 6 Analyst Projections For Corcept Therapeutics ↗

September 18, 2024

Via Benzinga

NASDAQ:CORT is not too expensive for the growth it is showing. ↗

September 17, 2024

Investors should take note ofCORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock that remains attractively priced.

Via Chartmill

NASDAQ:CORT: a strong growth stock preparing for the next leg up?. ↗

September 09, 2024

Exploring the Growth Potential of CORCEPT THERAPEUTICS INC (NASDAQ:CORT) as It Nears a Breakout.

Via Chartmill

NASDAQ:CORT: a strong growth stock preparing for the next leg up?. ↗

August 16, 2024

CORCEPT THERAPEUTICS INC (NASDAQ:CORT)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.

Via Chartmill

NASDAQ:CORT is not too expensive for the growth it is showing. ↗

August 05, 2024

Don't overlook NASDAQ:CORT—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering. ↗

August 27, 2024

Don't overlook CORCEPT THERAPEUTICS INC (NASDAQ:CORT)—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

Unveiling 8 Analyst Insights On Corcept Therapeutics ↗

July 30, 2024

Via Benzinga

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.